In Reply to "The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease"

被引：0
|
作者：
Horie, Shigeo [1 ]
Muto, Satoru [2 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Dept Urol, Bunkyo Ku, Hongo 3-1-3, Tokyo 1138431, Japan
[2] Teikyo Univ, Sch Med, Dept Urol, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Chronic Kidney Disease; Tempo; Kidney Function; Japanese Patient; Japanese Society;
D O I：
10.1007/s10157-015-1154-7
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：149 / 150
页数：2
相关论文
共 50 条
  • [1] In Reply to “The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease”
    Shigeo Horie
    Satoru Muto
    Clinical and Experimental Nephrology, 2016, 20 : 149 - 150
  • [2] The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease
    Kawada, Tomoyuki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2016, 20 (01) : 147 - 148
  • [3] The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease
    Tomoyuki Kawada
    Clinical and Experimental Nephrology, 2016, 20 : 147 - 148
  • [4] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Reply
    Torres, Vicente E.
    Gansevoort, Ron T.
    Czerwiec, Frank S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1259 - 1259
  • [5] Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Torres, Vicente E.
    Chapman, Arlene B.
    Devuyst, Olivier
    Gansevoort, Ron T.
    Grantham, Jared J.
    Higashihara, Eiji
    Perrone, Ronald D.
    Krasa, Holly B.
    Ouyang, John
    Czerwiec, Frank S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (25): : 2407 - 2418
  • [6] Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Jouret, Francois
    Krzesinski, Jean-Marie
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13): : 1258 - 1259
  • [7] Tolvaptan and Autosomal Dominant Polycystic Kidney Disease
    Ingelfinger, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1988 - 1989
  • [8] EFFECT OF TOLVAPTAN ON A BODYWATER BALANCE IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Makita, Minoru
    Nishio, Saori
    Kondo, Keiichi
    Kawashima, Keisuke
    Ishikawa, Yozo
    Hattanda, Fumihiko
    Kusunoki, Yoshihiro
    Matsuoka, Naoko
    Yamamoto, Junya
    Nakagaki, Tasuku
    Takeda, Hiroshi
    Atsumi, Tatsuya
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 93 - 93
  • [9] Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Baur, Brian P.
    Meaney, Calvin J.
    PHARMACOTHERAPY, 2014, 34 (06): : 605 - 616
  • [10] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Blair, Hannah A.
    DRUGS, 2019, 79 (03) : 303 - 313
12345